choline has been researched along with Cognition Disorders in 104 studies
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with higher choline and betaine levels had lower risk of cognitive impairment after ischemic stroke, supporting promising prognostic roles of choline pathway nutrients for poststroke cognitive impairment." | 9.41 | Choline Pathway Nutrients and Metabolites and Cognitive Impairment After Acute Ischemic Stroke. ( Bu, X; Che, B; Ju, Z; Lu, Z; Qian, S; Wang, A; Xu, T; Zhang, J; Zhang, Y; Zheng, X; Zhong, C, 2021) |
| "Nineteen subjects with bipolar disorder in remission, who reported subjective cognitive deficits, were treated with open-label galantamine-ER 8-24 mg/day for 4 months." | 9.14 | Galantamine-ER for cognitive dysfunction in bipolar disorder and correlation with hippocampal neuronal viability: a proof-of-concept study. ( Deckersbach, T; Iosifescu, DV; Moore, CM; Nierenberg, AA; Ostacher, MJ; Sachs, GS; Tilley, CA, 2009) |
| "We aimed to test whether in vivo levels of magnetic resonance spectroscopy (MRS) metabolites myo-inositol (mI), N-acetylaspartate (NAA), and choline are abnormal already during preclinical Alzheimer disease (AD), relating these changes to amyloid or tau pathology, and functional connectivity." | 7.83 | Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease. ( Blennow, K; Hansson, O; Minthon, L; Strandberg, O; Sundgren, PC; Voevodskaya, O; Wahlund, LO; Westman, E; Zetterberg, H, 2016) |
| "Our objective was to investigate the influence of hypertension on N-acetylaspartate (NAA) and choline (Cho) ratios in brain tissues in a community-dwelling elderly population." | 7.74 | N-acetylaspartate/creatine and choline/creatine ratios in the thalami, insular cortex and white matter as markers of hypertension and cognitive impairment in the elderly. ( Aho, SL; Bejot, Y; Ben Salem, D; Brunotte, F; Ricolfi, F; Rouaud, O; Tavernier, B; Walker, PM, 2008) |
| "As choline-containing compounds relate to membrane turnover, membrane dysfunction antedating neuronal death is suggested to occur in the frontal cortex in preclinical carriers of Huntington disease." | 7.74 | Decreased frontal choline and neuropsychological performance in preclinical Huntington disease. ( Alegret, M; Gómez-Ansón, B; Monte, GC; Muñoz, E; Sainz, A; Tolosa, E, 2007) |
| " In rats with beta-amyloid peptide-(25-35)-induced amnesia, CS enhanced passive avoidance performance and increased activity of brain choline acetyltransferase, as compared to control rats (saline)." | 7.74 | Dicholine salt of succinic acid, a neuronal insulin sensitizer, ameliorates cognitive deficits in rodent models of normal aging, chronic cerebral hypoperfusion, and beta-amyloid peptide-(25-35)-induced amnesia. ( Persiyantseva, NA; Pinelis, VG; Pomytkin, IA; Proshin, AT; Semenova, NA; Senilova, YE; Sherstnev, VV; Storozheva, ZI; Storozhevykh, TP; Zakharova, EI, 2008) |
| "Patients with higher choline and betaine levels had lower risk of cognitive impairment after ischemic stroke, supporting promising prognostic roles of choline pathway nutrients for poststroke cognitive impairment." | 5.41 | Choline Pathway Nutrients and Metabolites and Cognitive Impairment After Acute Ischemic Stroke. ( Bu, X; Che, B; Ju, Z; Lu, Z; Qian, S; Wang, A; Xu, T; Zhang, J; Zhang, Y; Zheng, X; Zhong, C, 2021) |
| "Nineteen subjects with bipolar disorder in remission, who reported subjective cognitive deficits, were treated with open-label galantamine-ER 8-24 mg/day for 4 months." | 5.14 | Galantamine-ER for cognitive dysfunction in bipolar disorder and correlation with hippocampal neuronal viability: a proof-of-concept study. ( Deckersbach, T; Iosifescu, DV; Moore, CM; Nierenberg, AA; Ostacher, MJ; Sachs, GS; Tilley, CA, 2009) |
| " Neuroimaging measures were central (ventricular) cerebral atrophy, lesion volume, and ratios of N-acetyl aspartate (NAA) to both creatine and choline." | 5.10 | Cognitive performance and MR markers of cerebral injury in cognitively impaired MS patients. ( Christodoulou, C; Huang, W; Krupp, LB; Li, L; Li, X; Liang, Z; MacAllister, WS; Melville, P; Morgan, T; Peyster, R; Roche, P; Roque, C; Scherl, WF; Tudorica, LA, 2003) |
| "Many of the neurochemical changes associated with aging brain, particularly lower choline acetyltransferase and higher monoamine oxidase, occur with greater severity in senile dementia, Alzheimer's type (SDAT)." | 4.76 | Chemotherapy of cognitive disorders in geriatric subjects. ( Gershon, S; Goodnick, P, 1984) |
| "We aimed to test whether in vivo levels of magnetic resonance spectroscopy (MRS) metabolites myo-inositol (mI), N-acetylaspartate (NAA), and choline are abnormal already during preclinical Alzheimer disease (AD), relating these changes to amyloid or tau pathology, and functional connectivity." | 3.83 | Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease. ( Blennow, K; Hansson, O; Minthon, L; Strandberg, O; Sundgren, PC; Voevodskaya, O; Wahlund, LO; Westman, E; Zetterberg, H, 2016) |
| "目的：应用磁共振氢质子波谱(1H-proton magnetic resonance spectroscopy，1H-MRS)检测合并认知功能障碍的多系统萎缩(multiple system atrophy，MSA)患者双侧额叶的代谢特点。方法：收集23例合并认知功能障碍的MSA患者(研究组1)及19例认知功能正常的MSA患者(研究组2)，另选48名与两组MSA患者年龄、性别匹配的正常人(正常对照组)均进行1H-MRS检查，其包括双侧额叶区N-乙酰天门冬氨酸(N-acetylaspartate，NAA)/肌酸(creatine，Cr)、胆碱(choline，Cho)/肌酸(Cr)、肌醇(myoinositol，mI)/肌酸(Cr)的测定。结果：合并认知障碍的MSA患者双侧额叶NAA/Cr值较认知正常的MSA患者和正常对照组显著降低(P<0." | 3.81 | [1H-proton magnetic resonance spectroscopy in patients with multiple system atrophy and cognitive dysfunction]. ( Hou, X; Jiang, H; Sun, Z; Tang, B; Xiang, X; Zhou, G, 2015) |
| "Our objective was to investigate the influence of hypertension on N-acetylaspartate (NAA) and choline (Cho) ratios in brain tissues in a community-dwelling elderly population." | 3.74 | N-acetylaspartate/creatine and choline/creatine ratios in the thalami, insular cortex and white matter as markers of hypertension and cognitive impairment in the elderly. ( Aho, SL; Bejot, Y; Ben Salem, D; Brunotte, F; Ricolfi, F; Rouaud, O; Tavernier, B; Walker, PM, 2008) |
| "As choline-containing compounds relate to membrane turnover, membrane dysfunction antedating neuronal death is suggested to occur in the frontal cortex in preclinical carriers of Huntington disease." | 3.74 | Decreased frontal choline and neuropsychological performance in preclinical Huntington disease. ( Alegret, M; Gómez-Ansón, B; Monte, GC; Muñoz, E; Sainz, A; Tolosa, E, 2007) |
| " In rats with beta-amyloid peptide-(25-35)-induced amnesia, CS enhanced passive avoidance performance and increased activity of brain choline acetyltransferase, as compared to control rats (saline)." | 3.74 | Dicholine salt of succinic acid, a neuronal insulin sensitizer, ameliorates cognitive deficits in rodent models of normal aging, chronic cerebral hypoperfusion, and beta-amyloid peptide-(25-35)-induced amnesia. ( Persiyantseva, NA; Pinelis, VG; Pomytkin, IA; Proshin, AT; Semenova, NA; Senilova, YE; Sherstnev, VV; Storozheva, ZI; Storozhevykh, TP; Zakharova, EI, 2008) |
| "Dementia was an independent predictor of metabolite values." | 2.73 | Magnetic resonance spectroscopy performance for detection of dementia, Alzheimer's disease and mild cognitive impairment in a community-based survey. ( Antúnez, C; Carles, R; Fortuna, L; García Santos, JM; Gavrila, D; Jiménez Veiga, J; Navarro, C; Parrilla, G; Salmerón, D; Tormo, MJ; Torres del Río, S, 2008) |
| "NAA/choline ratios were significantly reduced (P<0." | 2.71 | Childhood-onset growth hormone deficiency, cognitive function and brain N-acetylaspartate. ( Aleman, A; de Haan, EH; de Vries, R; de Winter, CF; Drent, ML; Kenemans, JL; Koppeschaar, HP; Lijffijt, M; van Dam, PS; van der Grond, J, 2005) |
| " Chronic administration of a false cholinergic transmitter in the diets of weanling rats mimicked such a state which, if maintained for a protracted period, produced many of the features of PDD in humans." | 2.39 | Continuing the search for cholinergic factors in cognitive dysfunction. ( Russell, RW, 1996) |
| "Human hepatic encephalopathy (HE) is identified by a new noninvasive test, proton magnetic resonance spectroscopy (1H MRS) applied to the brain in a few minutes." | 2.39 | Proton magnetic resonance spectroscopy: the new gold standard for diagnosis of clinical and subclinical hepatic encephalopathy? ( Blüml, S; Danielsen, ER; Ross, BD, 1996) |
| " Excitoxins when infused directly into the Nbm destroy non-specifically cell bodies but spare axons passing the injection site, whereas the specificity of AF64A to destroy cholinergic neurons depends on both the dosage applied and the site of injection." | 2.39 | Immunolesion by 192IgG-saporin of rat basal forebrain cholinergic system: a useful tool to produce cortical cholinergic dysfunction. ( Bigl, V; Rossner, S; Schliebs, R, 1996) |
| "Our results suggest that demyelination plays an important role in WM disruption post-injury in a subgroup of msTBI children and indicate the utility of multi-modal imaging." | 1.48 | Magnetic resonance spectroscopy of fiber tracts in children with traumatic brain injury: A combined MRS - Diffusion MRI study. ( Alger, J; Asarnow, RF; Babbitt, C; Babikian, T; Dennis, EL; Giza, CC; Jin, Y; Johnson, J; Mink, R; Olsen, A; Rashid, F; Thompson, PM; Villalon-Reina, JE, 2018) |
| "Choline (Ch) is an essential nutrient that acts as a cognitive facilitator when administered during perinatal periods, and it has been recognised as a 'pharmacological' agent that can ease cognitive dysfunctions provoked by exposure to damaging stimuli during early developmental stages." | 1.46 | Dietary choline during periadolescence attenuates cognitive damage caused by neonatal maternal separation in male rats. ( Carías Picón, D; de Brugada Sauras, I; Moreno Gudiño, H, 2017) |
| "Eighty six patients with Type 2 diabetes mellitus (T2DM) were enrolled for this study." | 1.43 | [Correlation between cognitive impairment and diabetic nephropathy in patients with Type 2 diabetes mellitus]. ( Niu, H; Shen, J; Shi, X; Wang, R; Wang, S; Wu, J; Yang, H; Zhang, Y; Zhou, S, 2016) |
| "Many patients with systemic lupus erythematosus (SLE) have working memory deficits." | 1.39 | White matter abnormalities and working memory impairment in systemic lupus erythematosus. ( Arciniegas, DB; Brown, MS; Duggan, E; Filley, CM; Kozora, E; West, S, 2013) |
| "Rats with the metabolic syndrome have ineffective inflammation-resolving mechanisms that represent plausible reasons for the exaggerated and persistent PCD." | 1.39 | Dysfunction of inflammation-resolving pathways is associated with exaggerated postoperative cognitive decline in a rat model of the metabolic syndrome. ( Britton, SL; Chawla, A; Feng, X; Koch, LG; Matthay, MA; Maze, M; Su, X; Terrando, N; Yan, Y, 2013) |
| "Heroin could be a cause more common than thought of leukoencephalopathy." | 1.38 | [Toxic leucoencephalopathy after use of sniffed heroin, an unrecognized form of beneficial evolution]. ( Cotton, F; Drouet, A; Felten, D; Guilloton, L; Havé, L; Lamboley, JL; Quesnel, L; St-Pierre, G, 2012) |
| " The results showed that piperine at all dosage range used in this study significantly improved memory impairment and neurodegeneration in hippocampus." | 1.36 | Piperine, the main alkaloid of Thai black pepper, protects against neurodegeneration and cognitive impairment in animal model of cognitive deficit like condition of Alzheimer's disease. ( Chonpathompikunlert, P; Muchimapura, S; Wattanathorn, J, 2010) |
| "Methionine choline treatment reversed long-term deficits in spatial learning and memory caused by Pb(2+) exposure in rats." | 1.36 | Methionine choline reverses lead-induced cognitive and N-methyl-d-aspartate receptor subunit 1 deficits. ( Bi, Y; Fan, G; Feng, C; Lin, F; Wang, C; Wu, F; Xiao, Y; Yan, J; Ye, W; Zhu, G, 2010) |
| "Previous studies have shown that COPD adversely affects distant organs and body systems, including the brain." | 1.35 | Modeling the impact of COPD on the brain. ( Anzai, Y; Aylward, E; Borson, S; Fields, J; Friedman, S; Mahurin, R; Richards, T; Scanlan, J; Yeh, S; Yukawa, M; Zuhr, E, 2008) |
| "Given the available therapies for Alzheimer's disease, early diagnosis is of paramount importance." | 1.33 | Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy. ( Fayed, N; Modrego, PJ; Pina, MA, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (3.85) | 18.7374 |
| 1990's | 10 (9.62) | 18.2507 |
| 2000's | 47 (45.19) | 29.6817 |
| 2010's | 42 (40.38) | 24.3611 |
| 2020's | 1 (0.96) | 2.80 |
| Authors | Studies |
|---|---|
| Ouach, A | 1 |
| Vercouillie, J | 1 |
| Bertrand, E | 1 |
| Rodrigues, N | 1 |
| Pin, F | 1 |
| Serriere, S | 1 |
| Boiaryna, L | 1 |
| Chartier, A | 1 |
| Percina, N | 1 |
| Tangpong, P | 1 |
| Gulhan, Z | 1 |
| Mothes, C | 1 |
| Deloye, JB | 1 |
| Guilloteau, D | 1 |
| Page, G | 1 |
| Suzenet, F | 1 |
| Buron, F | 1 |
| Chalon, S | 1 |
| Routier, S | 1 |
| Zhong, C | 1 |
| Lu, Z | 1 |
| Che, B | 1 |
| Qian, S | 1 |
| Zheng, X | 1 |
| Wang, A | 1 |
| Bu, X | 1 |
| Zhang, J | 1 |
| Ju, Z | 1 |
| Xu, T | 1 |
| Zhang, Y | 2 |
| Dennis, EL | 1 |
| Babikian, T | 2 |
| Alger, J | 1 |
| Rashid, F | 1 |
| Villalon-Reina, JE | 1 |
| Jin, Y | 1 |
| Olsen, A | 1 |
| Mink, R | 2 |
| Babbitt, C | 1 |
| Johnson, J | 1 |
| Giza, CC | 2 |
| Thompson, PM | 1 |
| Asarnow, RF | 2 |
| Wang, Y | 3 |
| Guan, X | 1 |
| Chen, X | 1 |
| Cai, Y | 1 |
| Ma, Y | 1 |
| Ma, J | 1 |
| Zhang, Q | 2 |
| Dai, L | 1 |
| Fan, X | 1 |
| Bai, Y | 1 |
| Gasparovic, C | 1 |
| Prestopnik, J | 1 |
| Thompson, J | 1 |
| Taheri, S | 1 |
| Huisa, B | 1 |
| Schrader, R | 1 |
| Adair, JC | 1 |
| Rosenberg, GA | 1 |
| Kozora, E | 3 |
| Arciniegas, DB | 4 |
| Duggan, E | 1 |
| West, S | 1 |
| Brown, MS | 3 |
| Filley, CM | 3 |
| Ge, X | 1 |
| Xu, XY | 1 |
| Feng, CH | 1 |
| Li, YL | 1 |
| Feng, B | 1 |
| Kolisnyk, B | 1 |
| Al-Onaizi, MA | 1 |
| Hirata, PH | 1 |
| Guzman, MS | 1 |
| Nikolova, S | 1 |
| Barbash, S | 1 |
| Soreq, H | 2 |
| Bartha, R | 1 |
| Prado, MA | 1 |
| Prado, VF | 1 |
| Schaevitz, L | 1 |
| Berger-Sweeney, J | 1 |
| Ricceri, L | 1 |
| Li, D | 1 |
| Bao, F | 1 |
| Ma, S | 1 |
| Guo, C | 1 |
| Jin, C | 1 |
| Zhang, M | 1 |
| Chang, L | 1 |
| Jiang, C | 1 |
| Cunningham, E | 1 |
| Buchthal, S | 1 |
| Douet, V | 1 |
| Andres, M | 1 |
| Ernst, T | 2 |
| Markakis, I | 1 |
| Alexopoulos, H | 1 |
| Poulopoulou, C | 1 |
| Akrivou, S | 1 |
| Papathanasiou, A | 1 |
| Katsiva, V | 1 |
| Lyrakos, G | 1 |
| Gekas, G | 1 |
| Dalakas, MC | 1 |
| Ramakrishnan, NK | 1 |
| Marosi, K | 1 |
| Nyakas, CJ | 1 |
| Kwizera, C | 1 |
| Elsinga, PH | 1 |
| Ishiwata, K | 1 |
| Luiten, PG | 1 |
| Dierckx, RA | 1 |
| van Waarde, A | 1 |
| Xiang, X | 1 |
| Hou, X | 1 |
| Sun, Z | 1 |
| Zhou, G | 1 |
| Tang, B | 1 |
| Jiang, H | 1 |
| Sailasuta, N | 1 |
| Ananworanich, J | 1 |
| Lerdlum, S | 1 |
| Sithinamsuwan, P | 1 |
| Fletcher, JL | 1 |
| Tipsuk, S | 1 |
| Pothisri, M | 1 |
| Jadwattanakul, T | 1 |
| Jirajariyavej, S | 1 |
| Chalermchai, T | 1 |
| Catella, S | 1 |
| Busovaca, E | 1 |
| Desai, A | 1 |
| Paul, R | 1 |
| Valcour, V | 1 |
| Moreno Gudiño, H | 1 |
| Carías Picón, D | 1 |
| de Brugada Sauras, I | 1 |
| Cheong, JL | 1 |
| Bainbridge, A | 1 |
| Anderson, PJ | 1 |
| Lee, KJ | 1 |
| Burnett, AC | 1 |
| Thompson, DK | 1 |
| Roberts, G | 1 |
| Wood, SJ | 1 |
| Doyle, LW | 1 |
| Robertson, NJ | 1 |
| Shi, X | 1 |
| Niu, H | 1 |
| Wang, R | 1 |
| Shen, J | 1 |
| Zhou, S | 1 |
| Yang, H | 1 |
| Wang, S | 2 |
| Wu, J | 1 |
| Van Dalen, YW | 1 |
| Blokhuis, C | 1 |
| Cohen, S | 1 |
| Ter Stege, JA | 1 |
| Teunissen, CE | 1 |
| Kuhle, J | 1 |
| Kootstra, NA | 1 |
| Scherpbier, HJ | 1 |
| Kuijpers, TW | 1 |
| Reiss, P | 1 |
| Majoie, CBLM | 1 |
| Caan, MWA | 1 |
| Pajkrt, D | 1 |
| Voevodskaya, O | 1 |
| Sundgren, PC | 1 |
| Strandberg, O | 1 |
| Zetterberg, H | 1 |
| Minthon, L | 1 |
| Blennow, K | 1 |
| Wahlund, LO | 1 |
| Westman, E | 1 |
| Hansson, O | 1 |
| García Santos, JM | 1 |
| Gavrila, D | 1 |
| Antúnez, C | 1 |
| Tormo, MJ | 1 |
| Salmerón, D | 1 |
| Carles, R | 1 |
| Jiménez Veiga, J | 1 |
| Parrilla, G | 1 |
| Torres del Río, S | 1 |
| Fortuna, L | 1 |
| Navarro, C | 1 |
| Paul, RH | 1 |
| Brickman, AM | 1 |
| Yiannoutsos, CT | 1 |
| Tate, DF | 1 |
| Cohen, RA | 1 |
| Navia, BA | 1 |
| Borson, S | 1 |
| Scanlan, J | 1 |
| Friedman, S | 1 |
| Zuhr, E | 1 |
| Fields, J | 1 |
| Aylward, E | 1 |
| Mahurin, R | 1 |
| Richards, T | 1 |
| Anzai, Y | 1 |
| Yukawa, M | 1 |
| Yeh, S | 1 |
| Ben Salem, D | 1 |
| Walker, PM | 1 |
| Bejot, Y | 1 |
| Aho, SL | 1 |
| Tavernier, B | 1 |
| Rouaud, O | 1 |
| Ricolfi, F | 1 |
| Brunotte, F | 1 |
| Sellin, AK | 1 |
| Shad, M | 1 |
| Tamminga, C | 1 |
| Kantarci, K | 5 |
| Petersen, RC | 5 |
| Przybelski, SA | 2 |
| Weigand, SD | 3 |
| Shiung, MM | 1 |
| Whitwell, JL | 1 |
| Negash, S | 1 |
| Ivnik, RJ | 5 |
| Boeve, BF | 5 |
| Knopman, DS | 4 |
| Smith, GE | 4 |
| Jack, CR | 5 |
| Erichsen, AK | 1 |
| Server, A | 1 |
| Landrø, NI | 1 |
| Sandvik, L | 1 |
| Tallaksen, CM | 1 |
| Kondziella, D | 1 |
| Danielsen, ER | 2 |
| Hansen, K | 1 |
| Thomsen, C | 1 |
| Jansen, EC | 1 |
| Arlien-Soeborg, P | 1 |
| Miller, DE | 1 |
| West, SG | 2 |
| Grimm, A | 1 |
| Zhang, L | 1 |
| Pilatus, U | 1 |
| Lais, C | 1 |
| Rochmont, Adu M | 1 |
| Kratzsch, T | 1 |
| Frölich, L | 1 |
| Maurer, K | 1 |
| Zanella, FE | 1 |
| Lanfermann, H | 2 |
| Pantel, J | 1 |
| Silver, JM | 1 |
| McAllister, TW | 1 |
| Tiehuis, A | 1 |
| van der Meer, F | 1 |
| Mali, W | 1 |
| Pleizier, M | 1 |
| Biessels, GJ | 1 |
| Kappelle, J | 1 |
| Luijten, P | 1 |
| Iosifescu, DV | 1 |
| Moore, CM | 1 |
| Deckersbach, T | 1 |
| Tilley, CA | 1 |
| Ostacher, MJ | 1 |
| Sachs, GS | 1 |
| Nierenberg, AA | 1 |
| Marion, SD | 1 |
| Copeland, S | 1 |
| Alger, JR | 1 |
| O'Neill, J | 2 |
| Cazalis, F | 1 |
| Vu, JA | 1 |
| Hilleary, SM | 1 |
| Kernan, CL | 1 |
| Newman, N | 1 |
| Chonpathompikunlert, P | 1 |
| Wattanathorn, J | 1 |
| Muchimapura, S | 1 |
| Govind, V | 1 |
| Gold, S | 1 |
| Kaliannan, K | 1 |
| Saigal, G | 1 |
| Falcone, S | 1 |
| Arheart, KL | 1 |
| Harris, L | 1 |
| Jagid, J | 1 |
| Maudsley, AA | 1 |
| Lee, JE | 1 |
| Jacques, PF | 2 |
| Dougherty, L | 1 |
| Selhub, J | 1 |
| Giovannucci, E | 1 |
| Zeisel, SH | 1 |
| Cho, E | 2 |
| Griffith, HR | 1 |
| Okonkwo, OC | 1 |
| den Hollander, JA | 1 |
| Belue, K | 1 |
| Copeland, J | 1 |
| Harrell, LE | 1 |
| Brockington, JC | 1 |
| Clark, DG | 1 |
| Marson, DC | 1 |
| Fan, G | 1 |
| Feng, C | 1 |
| Wu, F | 1 |
| Ye, W | 1 |
| Lin, F | 1 |
| Wang, C | 1 |
| Yan, J | 1 |
| Zhu, G | 1 |
| Xiao, Y | 1 |
| Bi, Y | 1 |
| Rao, V | 1 |
| Munro, CA | 1 |
| Rosenberg, P | 1 |
| Ward, J | 1 |
| Bertrand, M | 1 |
| Degoankar, M | 1 |
| Horská, A | 1 |
| Pham, D | 1 |
| Yousem, DM | 1 |
| Barker, PB | 1 |
| Premkumar, P | 1 |
| Parbhakar, VA | 1 |
| Fannon, D | 1 |
| Lythgoe, D | 1 |
| Williams, SC | 1 |
| Kuipers, E | 1 |
| Kumari, V | 1 |
| Watanabe, T | 1 |
| Shiino, A | 1 |
| Akiguchi, I | 1 |
| Bokemeyer, M | 1 |
| Ding, XQ | 1 |
| Goldbecker, A | 1 |
| Raab, P | 1 |
| Heeren, M | 1 |
| Arvanitis, D | 1 |
| Tillmann, HL | 1 |
| Weissenborn, K | 1 |
| Havé, L | 1 |
| Drouet, A | 1 |
| Lamboley, JL | 1 |
| Cotton, F | 1 |
| St-Pierre, G | 1 |
| Quesnel, L | 1 |
| Guilloton, L | 1 |
| Felten, D | 1 |
| Lowe, V | 1 |
| Senjem, ML | 1 |
| Roberts, R | 1 |
| Geda, YE | 1 |
| Seese, RR | 1 |
| Hudkins, M | 1 |
| Siddarth, P | 1 |
| Levitt, J | 1 |
| Tseng, B | 1 |
| Wu, KN | 1 |
| Caplan, R | 1 |
| Byrnes, V | 1 |
| Miller, A | 1 |
| Lowry, D | 1 |
| Hill, E | 1 |
| Weinstein, C | 1 |
| Alsop, D | 1 |
| Lenkinski, R | 1 |
| Afdhal, NH | 1 |
| Poly, C | 1 |
| Massaro, JM | 1 |
| Seshadri, S | 1 |
| Wolf, PA | 1 |
| Krall, E | 1 |
| Au, R | 1 |
| Van Kooij, BJ | 1 |
| Benders, MJ | 1 |
| Anbeek, P | 1 |
| Van Haastert, IC | 1 |
| De Vries, LS | 1 |
| Groenendaal, F | 1 |
| Srivastava, A | 1 |
| Yadav, SK | 1 |
| Borkar, VV | 1 |
| Yadav, A | 1 |
| Yachha, SK | 1 |
| Thomas, MA | 1 |
| Rathore, RK | 1 |
| Pandey, CM | 1 |
| Gupta, RK | 1 |
| Gonzales, MM | 1 |
| Tarumi, T | 1 |
| Eagan, DE | 1 |
| Tanaka, H | 1 |
| Vaghasia, M | 1 |
| Haley, AP | 1 |
| Corriveau, JA | 1 |
| Glenn, MJ | 1 |
| Yuan, J | 1 |
| Guo, X | 1 |
| Peng, P | 1 |
| Gu, H | 1 |
| Niu, S | 1 |
| Fregni, F | 1 |
| Chen, AC | 1 |
| Hu, W | 1 |
| Liu, X | 1 |
| Bai, Z | 1 |
| Liu, F | 1 |
| Li, M | 1 |
| Song, G | 1 |
| Xu, J | 1 |
| Su, X | 1 |
| Feng, X | 1 |
| Terrando, N | 1 |
| Yan, Y | 1 |
| Chawla, A | 1 |
| Koch, LG | 1 |
| Britton, SL | 1 |
| Matthay, MA | 1 |
| Maze, M | 1 |
| Weiss, U | 1 |
| Bacher, R | 1 |
| Vonbank, H | 1 |
| Kemmler, G | 1 |
| Lingg, A | 1 |
| Marksteiner, J | 1 |
| Reynolds, G | 1 |
| Edland, SD | 1 |
| Tangalos, EG | 3 |
| Christodoulou, C | 1 |
| Krupp, LB | 1 |
| Liang, Z | 1 |
| Huang, W | 1 |
| Melville, P | 1 |
| Roque, C | 1 |
| Scherl, WF | 1 |
| Morgan, T | 1 |
| MacAllister, WS | 1 |
| Li, L | 1 |
| Tudorica, LA | 1 |
| Li, X | 1 |
| Roche, P | 1 |
| Peyster, R | 1 |
| Waldman, AD | 1 |
| Rai, GS | 1 |
| Obergriesser, T | 1 |
| Ende, G | 1 |
| Braus, DF | 1 |
| Henn, FA | 1 |
| Sparkes, SJ | 1 |
| MacMaster, FP | 1 |
| Carrey, NC | 1 |
| Rispoli, V | 1 |
| Rotiroti, D | 1 |
| Carelli, V | 1 |
| Liberatore, F | 1 |
| Scipione, L | 1 |
| Marra, R | 1 |
| Giorgioni, G | 1 |
| Di Stefano, A | 1 |
| Frederick, BD | 1 |
| Lyoo, IK | 1 |
| Satlin, A | 1 |
| Ahn, KH | 1 |
| Kim, MJ | 1 |
| Yurgelun-Todd, DA | 1 |
| Cohen, BM | 1 |
| Renshaw, PF | 1 |
| Parry, L | 1 |
| Shores, A | 1 |
| Rae, C | 1 |
| Kemp, A | 1 |
| Waugh, MC | 1 |
| Chaseling, R | 1 |
| Joy, P | 1 |
| van Dam, PS | 1 |
| de Winter, CF | 1 |
| de Vries, R | 1 |
| van der Grond, J | 2 |
| Drent, ML | 1 |
| Lijffijt, M | 1 |
| Kenemans, JL | 1 |
| Aleman, A | 1 |
| de Haan, EH | 2 |
| Koppeschaar, HP | 1 |
| Ross, AJ | 1 |
| Sachdev, PS | 1 |
| Wen, W | 1 |
| Valenzuela, MJ | 1 |
| Brodaty, H | 1 |
| van Zandvoort, MJ | 1 |
| Kappelle, LJ | 1 |
| Modrego, PJ | 1 |
| Fayed, N | 1 |
| Pina, MA | 1 |
| Nelson, JA | 1 |
| Dou, H | 1 |
| Ellison, B | 1 |
| Uberti, M | 1 |
| Xiong, H | 1 |
| Anderson, E | 1 |
| Mellon, M | 1 |
| Gelbard, HA | 1 |
| Boska, M | 1 |
| Gendelman, HE | 1 |
| Meng, XM | 1 |
| Zhu, DM | 1 |
| Ruan, DY | 1 |
| She, JQ | 1 |
| Luo, L | 1 |
| Metastasio, A | 1 |
| Rinaldi, P | 1 |
| Tarducci, R | 2 |
| Mariani, E | 1 |
| Feliziani, FT | 1 |
| Cherubini, A | 2 |
| Pelliccioli, GP | 2 |
| Gobbi, G | 2 |
| Senin, U | 2 |
| Mecocci, P | 2 |
| Ellison, MC | 1 |
| Simon, JH | 1 |
| Azevedo, D | 2 |
| Bottino, CM | 2 |
| Tatsch, M | 2 |
| Hototian, SR | 2 |
| Bazzarella, MC | 2 |
| Castro, CC | 2 |
| Ilcol, YO | 1 |
| Basagan-Mogol, E | 1 |
| Cengiz, M | 1 |
| Ulus, IH | 1 |
| Coplan, JD | 1 |
| Mathew, SJ | 1 |
| Mao, X | 1 |
| Smith, EL | 1 |
| Hof, PR | 1 |
| Coplan, PM | 1 |
| Rosenblum, LA | 1 |
| Gorman, JM | 1 |
| Shungu, DC | 1 |
| Gunter, J | 1 |
| Reyes, D | 1 |
| Shiung, M | 1 |
| O'Brien, PC | 2 |
| Ohrmann, P | 1 |
| Siegmund, A | 1 |
| Suslow, T | 1 |
| Pedersen, A | 1 |
| Spitzberg, K | 1 |
| Kersting, A | 1 |
| Rothermundt, M | 1 |
| Arolt, V | 1 |
| Heindel, W | 1 |
| Pfleiderer, B | 1 |
| Gómez-Ansón, B | 2 |
| Alegret, M | 1 |
| Muñoz, E | 1 |
| Sainz, A | 1 |
| Monte, GC | 2 |
| Tolosa, E | 1 |
| Rami, L | 1 |
| Caprile, C | 1 |
| Sánchez-Valle, R | 1 |
| Bosch, B | 1 |
| Molinuevo, JL | 1 |
| Storozheva, ZI | 1 |
| Proshin, AT | 1 |
| Sherstnev, VV | 1 |
| Storozhevykh, TP | 1 |
| Senilova, YE | 1 |
| Persiyantseva, NA | 1 |
| Pinelis, VG | 1 |
| Semenova, NA | 1 |
| Zakharova, EI | 1 |
| Pomytkin, IA | 1 |
| Aztiria, E | 1 |
| Cataudella, T | 1 |
| Spampinato, S | 1 |
| Leanza, G | 1 |
| Goodnick, P | 1 |
| Gershon, S | 2 |
| Pomara, N | 1 |
| Banay-Schwartz, M | 1 |
| Block, R | 1 |
| Stanley, M | 1 |
| Meguro, K | 2 |
| Yamaguchi, S | 1 |
| Arai, H | 1 |
| Nakagawa, T | 1 |
| Doi, C | 1 |
| Yamada, M | 1 |
| Ikarashi, Y | 2 |
| Maruyama, Y | 2 |
| Sasaki, H | 2 |
| Buckley, PF | 1 |
| Moore, C | 1 |
| Long, H | 1 |
| Larkin, C | 1 |
| Thompson, P | 1 |
| Mulvany, F | 1 |
| Redmond, O | 1 |
| Stack, JP | 1 |
| Ennis, JT | 1 |
| Waddington, JL | 1 |
| Meyerhoff, DJ | 2 |
| MacKay, S | 1 |
| Bachman, L | 1 |
| Poole, N | 1 |
| Dillon, WP | 1 |
| Weiner, MW | 2 |
| Fein, G | 2 |
| Russell, RW | 1 |
| Ross, BD | 1 |
| Blüml, S | 1 |
| Schliebs, R | 1 |
| Rossner, S | 1 |
| Bigl, V | 1 |
| Handa, Y | 1 |
| Kaneko, M | 1 |
| Matuda, T | 1 |
| Kobayashi, H | 1 |
| Kubota, T | 1 |
| Brooks, WM | 2 |
| Jung, RE | 2 |
| Ford, CC | 1 |
| Greinel, EJ | 1 |
| Sibbitt, WL | 2 |
| Bloomer, C | 1 |
| Cardenas, V | 1 |
| Norman, D | 1 |
| Xu, YC | 1 |
| Campeau, NG | 1 |
| Kokmen, E | 1 |
| Sohn, YH | 1 |
| Jeong, Y | 1 |
| Kim, HS | 1 |
| Im, JH | 1 |
| Kim, JS | 1 |
| Stidley, CA | 1 |
| Petropoulos, H | 1 |
| Weers, DC | 1 |
| Friedman, SD | 1 |
| Barlow, MA | 1 |
| Yeo, RA | 1 |
| Schmidt, RH | 1 |
| Scholten, KJ | 1 |
| Maughan, PH | 1 |
| Erb, C | 1 |
| Troost, J | 1 |
| Kopf, S | 1 |
| Schmitt, U | 1 |
| Löffelholz, K | 1 |
| Klein, J | 1 |
| Malloy, CR | 1 |
| Catani, M | 1 |
| Howard, R | 1 |
| Piccirilli, M | 1 |
| Forton, DM | 1 |
| Thomas, HC | 1 |
| Murphy, CA | 1 |
| Allsop, JM | 1 |
| Foster, GR | 1 |
| Main, J | 1 |
| Wesnes, KA | 1 |
| Taylor-Robinson, SD | 1 |
| Yanai, M | 1 |
| Sekizawa, K | 1 |
| Yamamoto, M | 1 |
| Matsuzaki, Y | 1 |
| Takishima, T | 1 |
| Fisher, A | 1 |
| Brandeis, R | 1 |
| Pittel, Z | 1 |
| Karton, I | 1 |
| Sapir, M | 1 |
| Dachir, S | 1 |
| Levy, A | 1 |
| Heldman, E | 1 |
| Leathwood, PD | 1 |
| Schlosser, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Swedish BioFINDER Study: Early Diagnosis of Alzheimer's Disease - a Multidisciplinary Approach[NCT01208675] | 1,150 participants (Actual) | Observational | 2010-09-30 | Active, not recruiting | |||
| [NCT00181636] | 25 participants | Interventional | Completed | ||||
| Personalized Medicine in HCV Infection: Cognitive Impairments and Brain Anomalies in Chronic Hepatitis C Infected Individuals. Characterization and Potential Reversibility With Direct Antiviral Agents.[NCT02745132] | Phase 4 | 80 participants (Anticipated) | Interventional | 2016-06-30 | Not yet recruiting | ||
| A Study of the Cerebral Effect of Pegylated Interferon in Hepatitis C Positive Subjects[NCT00136214] | 22 participants (Actual) | Observational | 2004-03-31 | Completed | |||
| Minocycline Attenuate Postoperative Cognitive Dysfunction and Delirium: A Multicenter, Randomized, Double-Blind Clinical Trail[NCT02928692] | Phase 3 | 750 participants (Anticipated) | Interventional | 2016-11-30 | Recruiting | ||
| In Vivo Investigation on Mitochondrial Dysfunction in Post-COVID Fatigue and Cancer Fatigue.[NCT05753228] | 90 participants (Anticipated) | Interventional | 2022-12-09 | Recruiting | |||
| An Open-label Exploratory Study With Memantine: Correlation Between Proton Magnetic Resonance Spectroscopy, Cerebrospinal Fluid Biomarkers, and Cognition in Patients With Mild to Moderate Alzheimer's Disease[NCT00551161] | Phase 4 | 12 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A battery of pen and paper neurocognitive tests where subject means are reported compared to the normative Z score. Data is reported at baseline (T1), week 12 on treatment (T2) and 12 weeks after treatment (week 60, T3). Improvements are increases in the test result compared to baseline as determined against the Z score. tests performed included Hopkins learning trials (HVLT), a measure of of verbal learning and memory and the Roy-Osterrieth Complex figure test (ROCF) which evaluates visio-spatal abilities, memory, planning and working memory. Improvements in the score (increases in value compared, either less negative or more positive to the Z score) shown in the table are reflective of improvements in these neurocognitive parameters. (NCT00136214)
Timeframe: 18 months overall with measures performed at baseline (T1), week 12 (T2) and 12 weeks after end of treatment (T3) with PEG-IFN for 48 weeks which is 60 weeks post baseline and only done in treated group and not controls
| Intervention | Z-score (Mean) | |||||
|---|---|---|---|---|---|---|
| HVLT, Verbal Learning Total, T1 | HVLT, Verbal Learning Total, T2 | HVLT, Verbal Learning Total, T3 | ROCF, T1 | ROCF, T2 | ROCF,T3 | |
| Interferon Treated Group | -1.43 | -0.78 | -0.7 | 0.34 | 0.15 | 0.33 |
| Non-treated Cohort Control | -2.0 | -1.16 | NA | -1.0 | 0.05 | NA |
Evaluation of changes in MR spectroscopy. reductions in ratio of Cho and MI reflect improvements in cerebral inflammation and improvement in cognition. Increases in the NAA ratio are suggestive of improvement in cognitive function. (NCT00136214)
Timeframe: 18 months overall with measures performed at baseline (T1), week 12 (T2) and 12 weeks after end of treatment (T3) with PEG-IFN for 48 weeks which is 60 weeks post baseline
| Intervention | ratio (Mean) | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Basal Ganglia, T1, Cho/Cr | Basal Ganglia,T2, Cho/Cr | Basal Ganglia, T3, Cho/Cr | Basal Ganglia, T1, MI/Cr | Basal Ganglia T2. MI/C | Basal Ganglia T3, MI/C | Frontal Cortex T1, Cho/Cr | Frontal Cortex T2, Cho/Cr | Frontal Cortex T3, Cho/Cr | Basal Ganglia T1, NAA/Cr | Basal Ganglia T2, NAA/Cr | Basal Ganglia T3, NAA/Cr | Frontal Cortex T1,Mi/Cr | Frontal Cortex T2, MI/Cr | Frontal Cortex T3, MI/Cr | Frontal Cortex T1, NAA/Cr | Frontal Cortex T2, NAA/Cr | Frontal Cortex T3, NAA/Cr | DLPFC T1, Cho/Cr | DLPFC T2, Cho/Cr | DLPFC T3, Cho/Cr | DLPFC T1, MI/Cr | DLPFC T2, MI/Cr | DLPFC T3/ MI/Cr | DLPFC T1, NAA/Cr | DLPFC T2, NAA/Cr | DLFPC T3, NAA/Cr | |
| Interferon Treated Group | 0.42 | 0.28 | 0.34 | 0.78 | 0.71 | 0.75 | 0.29 | 0.26 | 0.29 | 1.26 | 1.25 | 1.09 | 0.68 | 0.75 | 0.71 | 1.73 | 1.74 | 1.75 | 0.31 | 0.25 | 0.26 | 0.79 | 0.75 | 0.93 | 1.72 | 1.65 | 1.78 |
| Non-treated Cohort Control | 0.30 | 0.28 | NA | 0.78 | 0.72 | NA | 0.28 | 0.29 | NA | 1.28 | 1.07 | NA | 0.77 | 1.19 | NA | 1.55 | 1.72 | NA | 0.27 | 0.27 | NA | 0.78 | 0.86 | NA | 1.61 | 1.60 | NA |
Ratios of myo-inositol (mI), N-acetylaspartate (NAA), total creatine (Cr), and choline (Cho) by single voxel 1H MRS (proton magnetic resonance spectroscopy). Mean (± SD) metabolite levels (normalized to T2-corrected water signal intensity) and metabolite ratios for Alzheimer's disease subjects at baseline (t0), after 24 weeks of ongoing monotherapy with stable-dose cholinesterase inhibitor (t1), and after another 24 weeks of combination therapy with memantine in addition to stable-dose cholinesterase inhibitor (t2). The Wilcoxon signed-rank test was used to examine whether the change between t0 and t1 differed from the change between t1 and t2 [(t2 - t1) - (t1 - t0)]. (NCT00551161)
Timeframe: Baseline, 24 weeks, and 48 weeks
| Intervention | ratio (normalized to T2-corrected water (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Change in NAA [(t2-t1) - (t1-t0)] | Change in Cr [(t2-t1) - (t1-t0)] | Change in Cho [(t2-t1) - (t1-t0)] | Change in mI [(t2-t1) - (t1-t0)] | Change in NAA/Cr [(t2-t1) - (t1-t0)] | Change in Cho/Cr [(t2-t1) - (t1-t0)] | Change in mI/Cr [(t2-t1) - (t1-t0)] | Change in NAA/Cho [(t2-t1) - (t1-t0)] | Change in NAA/mI [(t2-t1) - (t1-t0)] | |
| Memantine | -54 | -2 | 9 | 16 | -0.09 | 0.02 | 0.04 | -0.26 | -0.35 |
8 reviews available for choline and Cognition Disorders
| Article | Year |
|---|---|
One-carbon metabolism in neurodevelopmental disorders: using broad-based nutraceutics to treat cognitive deficits in complex spectrum disorders.
Topics: Carbon; Choline; Cognition Disorders; Developmental Disabilities; Dietary Supplements; Folic Acid; H | 2014 |
Muscarinic agonists for the treatment of cognition in schizophrenia.
Topics: Animals; Antipsychotic Agents; Choline; Cognition Disorders; Disease Models, Animal; Humans; Muscari | 2008 |
Depression and cognitive complaints following mild traumatic brain injury.
Topics: Antidepressive Agents, Tricyclic; Brain; Brain Injuries; Central Nervous System Stimulants; Choline; | 2009 |
Chemotherapy of cognitive disorders in geriatric subjects.
Topics: Adrenocorticotropic Hormone; Aged; Aging; Alzheimer Disease; Arecoline; Brain Chemistry; Choline; Co | 1984 |
Continuing the search for cholinergic factors in cognitive dysfunction.
Topics: Animals; Apoptosis; Choline; Choline Deficiency; Cognition Disorders; Down-Regulation; Humans; Recep | 1996 |
Proton magnetic resonance spectroscopy: the new gold standard for diagnosis of clinical and subclinical hepatic encephalopathy?
Topics: Animals; Astrocytes; Brain; Choline; Cognition Disorders; Disease Models, Animal; Glutamine; Hepatic | 1996 |
Immunolesion by 192IgG-saporin of rat basal forebrain cholinergic system: a useful tool to produce cortical cholinergic dysfunction.
Topics: Acetylcholine; Acetylcholinesterase; Alzheimer Disease; Animals; Antibodies, Monoclonal; Cerebral Co | 1996 |
Phosphatidylcholine, choline and cholinergic function.
Topics: Acetyl Coenzyme A; Acetylcholine; Aging; Alzheimer Disease; Animals; Avoidance Learning; Biological | 1986 |
8 trials available for choline and Cognition Disorders
| Article | Year |
|---|---|
Choline Pathway Nutrients and Metabolites and Cognitive Impairment After Acute Ischemic Stroke.
Topics: Aged; Antihypertensive Agents; Brain Ischemia; China; Choline; Cognition; Cognition Disorders; Cogni | 2021 |
Magnetic resonance spectroscopy performance for detection of dementia, Alzheimer's disease and mild cognitive impairment in a community-based survey.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain; Choline; Cognition Disorders; Crea | 2008 |
Galantamine-ER for cognitive dysfunction in bipolar disorder and correlation with hippocampal neuronal viability: a proof-of-concept study.
Topics: Adolescent; Adult; Aged; Aspartic Acid; Bipolar Disorder; Brain Mapping; Choline; Cholinesterase Inh | 2009 |
Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition.
Topics: Adult; Aged; Antiviral Agents; Aspartic Acid; Basal Ganglia; Choline; Cognition; Cognition Disorders | 2012 |
Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition.
Topics: Adult; Aged; Antiviral Agents; Aspartic Acid; Basal Ganglia; Choline; Cognition; Cognition Disorders | 2012 |
Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition.
Topics: Adult; Aged; Antiviral Agents; Aspartic Acid; Basal Ganglia; Choline; Cognition; Cognition Disorders | 2012 |
Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition.
Topics: Adult; Aged; Antiviral Agents; Aspartic Acid; Basal Ganglia; Choline; Cognition; Cognition Disorders | 2012 |
Cognitive performance and MR markers of cerebral injury in cognitively impaired MS patients.
Topics: Adult; Aspartic Acid; Atrophy; Axons; Biomarkers; Cerebral Cortex; Choline; Cognition Disorders; Cre | 2003 |
Childhood-onset growth hormone deficiency, cognitive function and brain N-acetylaspartate.
Topics: Adolescent; Adult; Age of Onset; Aging; Aspartic Acid; Brain; Brain Chemistry; Choline; Cognition; C | 2005 |
1H MRS in stroke patients with and without cognitive impairment.
Topics: Aged; Aged, 80 and over; Aspartic Acid; Biomarkers; Cerebral Cortex; Choline; Cognition Disorders; C | 2005 |
Proton spectroscopy in Alzheimer's disease and cognitive impairment no dementia: a community-based study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Atrophy; Brain; Choline; Cognition Disord | 2008 |
88 other studies available for choline and Cognition Disorders
| Article | Year |
|---|---|
Bis(het)aryl-1,2,3-triazole quinuclidines as α7 nicotinic acetylcholine receptor ligands: Synthesis, structure affinity relationships, agonism activity, [
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Brain; Cell Survival; Cognition Disorders; Dose-Re | 2019 |
Magnetic resonance spectroscopy of fiber tracts in children with traumatic brain injury: A combined MRS - Diffusion MRI study.
Topics: Adolescent; Anisotropy; Aspartic Acid; Brain Damage, Chronic; Brain Injuries, Traumatic; Child; Chol | 2018 |
Choline Supplementation Ameliorates Behavioral Deficits and Alzheimer's Disease-Like Pathology in Transgenic APP/PS1 Mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anxiety; Behavior, Animal; Choline; Cholinergic N | 2019 |
1H-MR spectroscopy metabolite levels correlate with executive function in vascular cognitive impairment.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Biomarkers; Brain Ischemia; Choline; Cogn | 2013 |
White matter abnormalities and working memory impairment in systemic lupus erythematosus.
Topics: Choline; Cognition Disorders; Creatinine; Frontal Lobe; Humans; Leukoencephalopathies; Lupus Erythem | 2013 |
Relationships among serum C-reactive protein, receptor for advanced glycation products, metabolic dysfunction, and cognitive impairments.
Topics: Adult; Aged; Aspartic Acid; C-Reactive Protein; Cholesterol; Choline; Cognition Disorders; Female; H | 2013 |
Forebrain deletion of the vesicular acetylcholine transporter results in deficits in executive function, metabolic, and RNA splicing abnormalities in the prefrontal cortex.
Topics: Acetylcholine; Animals; Aspartic Acid; Choice Behavior; Choline; Cholinesterase Inhibitors; Cognitio | 2013 |
Thalamic metabolic alterations with cognitive dysfunction in idiopathic trigeminal neuralgia: a multivoxel spectroscopy study.
Topics: Adult; Aged; Aspartic Acid; Case-Control Studies; Choline; Cognition Disorders; Creatine; Female; Hu | 2014 |
Effects of APOE ε4, age, and HIV on glial metabolites and cognitive deficits.
Topics: Adult; Aging; Apolipoprotein E4; Choline; Cognition Disorders; Cross-Sectional Studies; Female; Fron | 2014 |
Immunotherapy-responsive limbic encephalitis with antibodies to glutamic acid decarboxylase.
Topics: Antibodies; Aspartic Acid; Choline; Cognition Disorders; Creatine; Female; Glutamate Decarboxylase; | 2014 |
Altered sigma-1 receptor expression in two animal models of cognitive impairment.
Topics: Animals; Blotting, Western; Choline; Cognition Disorders; Disease Models, Animal; Kinetics; Male; Ra | 2015 |
[1H-proton magnetic resonance spectroscopy in patients with multiple system atrophy and
cognitive dysfunction].
Topics: Aspartic Acid; Choline; Cognition Disorders; Creatine; Frontal Lobe; Humans; Inositol; Multiple Syst | 2015 |
Neuronal-Glia Markers by Magnetic Resonance Spectroscopy in HIV Before and After Combination Antiretroviral Therapy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Aspartic Acid; Biomarkers; Brain; Cho | 2016 |
Dietary choline during periadolescence attenuates cognitive damage caused by neonatal maternal separation in male rats.
Topics: Animals; Animals, Newborn; Choline; Choline Deficiency; Cognition Disorders; Dietary Supplements; Ma | 2017 |
Altered posterior cingulate brain metabolites and cognitive dysfunction in preterm adolescents.
Topics: Adolescent; Aspartic Acid; Australia; Brain; Cell Membrane; Choline; Cognition; Cognition Disorders; | 2016 |
[Correlation between cognitive impairment and diabetic nephropathy in patients with Type 2 diabetes mellitus].
Topics: Adult; Aspartic Acid; Case-Control Studies; Cerebrum; Choline; Cognition; Cognition Disorders; Creat | 2016 |
Neurometabolite Alterations Associated With Cognitive Performance in Perinatally HIV-Infected Children.
Topics: Adolescent; AIDS Dementia Complex; Aspartic Acid; Brain; CD4 Lymphocyte Count; Child; Choline; Cogni | 2016 |
Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease.
Topics: Aged; Alzheimer Disease; Amyloidogenic Proteins; Apolipoprotein E4; Aspartic Acid; Brain; Brain Mapp | 2016 |
Relative sensitivity of magnetic resonance spectroscopy and quantitative magnetic resonance imaging to cognitive function among nondemented individuals infected with HIV.
Topics: Adult; Affect; Aspartic Acid; Choline; Cognition Disorders; Creatine; Female; HIV Infections; Humans | 2008 |
Modeling the impact of COPD on the brain.
Topics: Affect; Aged; Brain; Brain Diseases; Choline; Cognition; Cognition Disorders; Disease Progression; F | 2008 |
N-acetylaspartate/creatine and choline/creatine ratios in the thalami, insular cortex and white matter as markers of hypertension and cognitive impairment in the elderly.
Topics: Aged; Aged, 80 and over; Aging; Aspartic Acid; Biomarkers; Cerebral Cortex; Choline; Cognition Disor | 2008 |
Hippocampal volumes, proton magnetic resonance spectroscopy metabolites, and cerebrovascular disease in mild cognitive impairment subtypes.
Topics: Aged; Aged, 80 and over; Aspartic Acid; Case-Control Studies; Cerebrovascular Disorders; Chi-Square | 2008 |
Proton magnetic resonance spectroscopy and cognition in patients with spastin mutations.
Topics: Adenosine Triphosphatases; Adult; Aspartic Acid; Biomarkers; Choline; Cognition Disorders; Creatine; | 2009 |
1H MR spectroscopy of gray and white matter in carbon monoxide poisoning.
Topics: Adolescent; Adult; Aspartic Acid; Brain; Carbon Monoxide Poisoning; Choline; Cognition Disorders; Cr | 2009 |
White matter microstructure and cognition in non-neuropsychiatric systemic lupus erythematosus.
Topics: Adult; Aspartic Acid; Axons; Brain; Brain Chemistry; Choline; Cognition; Cognition Disorders; Creati | 2009 |
Conversion to dementia in mild cognitive impairment is associated with decline of N-actylaspartate and creatine as revealed by magnetic resonance spectroscopy.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Choline; Cognition; Cognition Disorders; Creatine; De | 2009 |
MR spectroscopy of cerebral white matter in type 2 diabetes; no association with clinical variables and cognitive performance.
Topics: Aged; Aged, 80 and over; Aspartic Acid; Brain; Choline; Cognition; Cognition Disorders; Creatine; Di | 2010 |
Metabolic levels in the corpus callosum and their structural and behavioral correlates after moderate to severe pediatric TBI.
Topics: Adolescent; Age Factors; Aging; Anisotropy; Aspartic Acid; Axons; Biomarkers; Brain Injuries; Child; | 2010 |
Piperine, the main alkaloid of Thai black pepper, protects against neurodegeneration and cognitive impairment in animal model of cognitive deficit like condition of Alzheimer's disease.
Topics: Acetylcholinesterase; Alkaloids; Alzheimer Disease; Animals; Aziridines; Benzodioxoles; Choline; Cog | 2010 |
Whole-brain proton MR spectroscopic imaging of mild-to-moderate traumatic brain injury and correlation with neuropsychological deficits.
Topics: Adolescent; Adult; Aspartic Acid; Biomarkers; Brain; Brain Injuries; Choline; Cognition Disorders; C | 2010 |
Are dietary choline and betaine intakes determinants of total homocysteine concentration?
Topics: Betaine; Cardiovascular Diseases; Choline; Cognition Disorders; Diet; Female; Folic Acid; Homocystei | 2010 |
Brain metabolic correlates of decision making in amnestic mild cognitive impairment.
Topics: Aged; Amnesia; Aspartic Acid; Brain; Choline; Cognition Disorders; Creatine; Decision Making; Female | 2010 |
Methionine choline reverses lead-induced cognitive and N-methyl-d-aspartate receptor subunit 1 deficits.
Topics: Animals; Brain; Choline; Cognition Disorders; D-Aspartic Acid; Hippocampus; Male; Memory; Methionine | 2010 |
Neuroanatomical correlates of depression in post traumatic brain injury: preliminary results of a pilot study.
Topics: Adult; Aspartic Acid; Basal Ganglia; Brain; Brain Injuries; Case-Control Studies; Choline; Cognition | 2010 |
N-acetyl aspartate concentration in the anterior cingulate cortex in patients with schizophrenia: a study of clinical and neuropsychological correlates and preliminary exploration of cognitive behaviour therapy effects.
Topics: Adolescent; Adult; Analysis of Variance; Aspartic Acid; Child; Choline; Cognition Disorders; Cogniti | 2010 |
Absolute quantification in proton magnetic resonance spectroscopy is useful to differentiate amnesic mild cognitive impairment from Alzheimer's disease and healthy aging.
Topics: Aged; Aging; Alzheimer Disease; Amnesia; Analysis of Variance; Aspartic Acid; Biomarkers; Brain Chem | 2010 |
Evidence for neuroinflammation and neuroprotection in HCV infection-associated encephalopathy.
Topics: Adult; Aged; Aspartic Acid; Brain; Brain Mapping; Case-Control Studies; Choline; Cognition Disorders | 2011 |
[Toxic leucoencephalopathy after use of sniffed heroin, an unrecognized form of beneficial evolution].
Topics: Administration, Inhalation; Biopsy; Brain Chemistry; Brain Edema; Choline; Cognition Disorders; Demy | 2012 |
Magnetic resonance spectroscopy, β-amyloid load, and cognition in a population-based sample of cognitively normal older adults.
Topics: Aged; Aged, 80 and over; Amyloid beta-Peptides; Choline; Cognition; Cognition Disorders; Creatinine; | 2011 |
Proton magnetic resonance spectroscopy and thought disorder in childhood schizophrenia.
Topics: Adolescent; Analysis of Variance; Aspartic Acid; Brain; Child; Choline; Cognition Disorders; Creatin | 2011 |
The relation of dietary choline to cognitive performance and white-matter hyperintensity in the Framingham Offspring Cohort.
Topics: Adult; Aged; Aged, 80 and over; Brain; Choline; Cognition; Cognition Disorders; Cohort Studies; Diet | 2011 |
Cerebellar volume and proton magnetic resonance spectroscopy at term, and neurodevelopment at 2 years of age in preterm infants.
Topics: Aspartic Acid; Brain Mapping; Cerebellum; Child, Preschool; Choline; Cognition Disorders; Developmen | 2012 |
Serial evaluation of children with ALF with advanced MRI, serum proinflammatory cytokines, thiamine, and cognition assessment.
Topics: Brain; Brain Edema; Case-Control Studies; Child; Child, Preschool; Choline; Cognition; Cognition Dis | 2012 |
Indirect effects of elevated body mass index on memory performance through altered cerebral metabolite concentrations.
Topics: Adult; Aspartic Acid; Biomarkers; Body Mass Index; Brain; Choline; Cognition Disorders; Creatine; Fe | 2012 |
Postnatal choline levels mediate cognitive deficits in a rat model of schizophrenia.
Topics: Animals; Choline; Choline Deficiency; Cognition Disorders; Disease Models, Animal; Dizocilpine Malea | 2012 |
Neurochemical correlates of cognitive dysfunction in patients with leukoaraiosis: a proton magnetic resonance spectroscopy study.
Topics: Aged; Aspartic Acid; Brain Chemistry; Choline; Cognition Disorders; Female; Humans; Leukoaraiosis; M | 2012 |
Reduced posterior cingulate glutamate measured by magnetic resonance spectroscopy in hyperthyroidism.
Topics: Adult; Aspartic Acid; Choline; Cognition Disorders; Creatine; Female; Glutamic Acid; Gyrus Cinguli; | 2012 |
Dysfunction of inflammation-resolving pathways is associated with exaggerated postoperative cognitive decline in a rat model of the metabolic syndrome.
Topics: Animals; Anti-Inflammatory Agents; CD3 Complex; Cell Polarity; Choline; Cognition Disorders; Disease | 2013 |
Cognitive impairment: assessment with brain magnetic resonance imaging and proton magnetic resonance spectroscopy.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Brain Chemistry; Choline; Cognition Disorders; Creati | 2003 |
Proton MR spectroscopy in mild cognitive impairment and Alzheimer disease: comparison of 1.5 and 3 T.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain; Choline; Cognition Disorders; Crea | 2003 |
The relationship between cognitive impairment and in vivo metabolite ratios in patients with clinical Alzheimer's disease and vascular dementia: a proton magnetic resonance spectroscopy study.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Choline; Cognition Disorders; Creatinine; Dementia, Vascular | 2003 |
Long-term follow-up of magnetic resonance-detectable choline signal changes in the hippocampus of patients treated with electroconvulsive therapy.
Topics: Aspartic Acid; Choline; Cognition Disorders; Creatine; Depressive Disorder, Major; Electroconvulsive | 2003 |
Proton magnetic resonance spectroscopy and cognitive function in pediatric attention-deficit/hyperactive disorder.
Topics: Aspartic Acid; Attention Deficit Disorder with Hyperactivity; Brain Stem; Child; Choline; Cognition | 2004 |
Choline pivaloyl esters improve in rats cognitive and memory performances impaired by scopolamine treatment or lesions of the nucleus basalis of Meynert.
Topics: Acetylcholinesterase; Analysis of Variance; Animals; Basal Nucleus of Meynert; Cell Count; Choline; | 2004 |
In vivo proton magnetic resonance spectroscopy of the temporal lobe in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Aspartic Acid; Brain Mapping; Case | 2004 |
An investigation of neuronal integrity in severe paediatric traumatic brain injury.
Topics: Adolescent; Age Factors; Aspartic Acid; Brain Injuries; Child; Choline; Cognition Disorders; Creatin | 2004 |
Cognitive deficits and changes in neurometabolites after a lacunar infarct.
Topics: Aged; Analysis of Variance; Aspartic Acid; Brain Infarction; Case-Control Studies; Choline; Cognitio | 2005 |
Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy.
Topics: Aged; Alzheimer Disease; Aspartic Acid; Brain; Choline; Cognition Disorders; Cohort Studies; Creatin | 2005 |
Coregistration of quantitative proton magnetic resonance spectroscopic imaging with neuropathological and neurophysiological analyses defines the extent of neuronal impairments in murine human immunodeficiency virus type-1 encephalitis.
Topics: AIDS Dementia Complex; Animals; Aspartic Acid; Brain Mapping; Calcium-Binding Proteins; Capsid Prote | 2005 |
Effects of chronic lead exposure on 1H MRS of hippocampus and frontal lobes in children.
Topics: Aspartic Acid; Cell Membrane; Cell Survival; Child; Choline; Chronic Disease; Cognition Disorders; C | 2005 |
Conversion of MCI to dementia: Role of proton magnetic resonance spectroscopy.
Topics: Aged; Amnesia; Aspartic Acid; Cerebral Cortex; Choline; Cognition Disorders; Creatine; Dementia; Dis | 2006 |
Cognition, MRS neurometabolites, and MRI volumetrics in non-neuropsychiatric systemic lupus erythematosus: preliminary data.
Topics: Adult; Aspartic Acid; Attention; Brain; Brain Chemistry; Choline; Cognition Disorders; Female; Front | 2005 |
[Proton spectroscopy in Alzheimer's disease and cognitive impairment not dementia: a community study].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Case-Control Studies; Choline; Cognition | 2005 |
Elevation of serum cerebral injury markers correlates with serum choline decline after coronary artery bypass grafting surgery.
Topics: Adult; Aged; Biomarkers; Brain Diseases; Choline; Cognition Disorders; Coronary Artery Bypass; Femal | 2006 |
Decreased choline and creatine concentrations in centrum semiovale in patients with generalized anxiety disorder: relationship to IQ and early trauma.
Topics: Adult; Anxiety Disorders; Body Mass Index; Choline; Cognition Disorders; Creatine; Frontal Lobe; Fun | 2006 |
Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Aspartic Acid; Choline; Cognition | 2007 |
Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study.
Topics: Adult; Aged; Antipsychotic Agents; Aspartic Acid; Choline; Chronic Disease; Cognition Disorders; Cre | 2007 |
Decreased frontal choline and neuropsychological performance in preclinical Huntington disease.
Topics: Adult; Basal Ganglia; Cell Membrane; Choline; Cognition; Cognition Disorders; Down-Regulation; Femal | 2007 |
Naming is associated with left temporal pole metabolite levels in neurodegenerative diseases.
Topics: Aged; Amnesia; Anomia; Aspartic Acid; Choline; Cognition Disorders; Creatine; Dementia; Female; Huma | 2008 |
Dicholine salt of succinic acid, a neuronal insulin sensitizer, ameliorates cognitive deficits in rodent models of normal aging, chronic cerebral hypoperfusion, and beta-amyloid peptide-(25-35)-induced amnesia.
Topics: Aging; Amnesia; Amyloid beta-Peptides; Animals; Cerebrovascular Circulation; Choline; Cognition Diso | 2008 |
Septal grafts restore cognitive abilities and amyloid precursor protein metabolism.
Topics: Acetylcholinesterase; Amyloid beta-Protein Precursor; Animals; Antibodies, Monoclonal; Cerebral Cort | 2009 |
Elevation of RBC glycine and choline levels in geriatric patients treated with lithium.
Topics: Aged; Alzheimer Disease; Choline; Cognition Disorders; Dementia; Erythrocytes; Female; Glycine; Huma | 1983 |
Nicotine improves cognitive disturbance in senescence-accelerated mice.
Topics: Acetylcholine; Aging; Animals; Avoidance Learning; Body Weight; Brain Chemistry; Choline; Cognition | 1994 |
1H-magnetic resonance spectroscopy of the left temporal and frontal lobes in schizophrenia: clinical, neurodevelopmental, and cognitive correlates.
Topics: Adult; Choline; Cognition Disorders; Creatine; Female; Frontal Lobe; Humans; Magnetic Resonance Spec | 1994 |
Reduced brain N-acetylaspartate suggests neuronal loss in cognitively impaired human immunodeficiency virus-seropositive individuals: in vivo 1H magnetic resonance spectroscopic imaging.
Topics: Adult; Aspartic Acid; Brain; Choline; Cognition Disorders; Creatine; HIV Seropositivity; Humans; Mag | 1993 |
In vivo proton magnetic resonance spectroscopy for metabolic changes in brain during chronic cerebral vasospasm in primates.
Topics: Animals; Aspartic Acid; Brain; Brain Ischemia; Cerebral Angiography; Cerebrovascular Circulation; Ch | 1997 |
Relationship between neurometabolite derangement and neurocognitive dysfunction in systemic lupus erythematosus.
Topics: Adult; Aspartic Acid; Brain; Choline; Cognition Disorders; Creatine; Female; Humans; Lupus Erythemat | 1999 |
Elevated subcortical choline metabolites in cognitively and clinically asymptomatic HIV+ patients.
Topics: Adult; Aspartic Acid; Brain Chemistry; Choline; Cognition Disorders; HIV Infections; HIV Seropositiv | 1999 |
Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: A 1H MRS study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Brain Mapping; Choline; Cognition Disorde | 2000 |
The brain lesion responsible for parkinsonism after carbon monoxide poisoning.
Topics: Aspartic Acid; Brain Chemistry; Carbon Monoxide Poisoning; Carrier Proteins; Choline; Cognition Diso | 2000 |
Metabolic and cognitive response to human traumatic brain injury: a quantitative proton magnetic resonance study.
Topics: Adolescent; Adult; Aged; Aspartic Acid; Brain Injuries; Choline; Cognition Disorders; Creatinine; Cr | 2000 |
Cognitive impairment and synaptosomal choline uptake in rats following impact acceleration injury.
Topics: Acceleration; Animals; Binding, Competitive; Brain; Brain Injuries; Choline; Cognition Disorders; Ma | 2000 |
Compensatory mechanisms enhance hippocampal acetylcholine release in transgenic mice expressing human acetylcholinesterase.
Topics: Acetylcholine; Acetylcholinesterase; Aging; Anesthetics, Inhalation; Animals; Choline; Cholinesteras | 2001 |
Correlation of cerebral metabolites with clinical outcome among patients with severe congestive heart failure.
Topics: Aspartic Acid; Brain; Choline; Cognition Disorders; Creatine; Disease Progression; Heart Failure; Hu | 2001 |
(1)H-MR spectroscopy differentiates mild cognitive impairment from normal brain aging.
Topics: Aged; Aged, 80 and over; Aging; Alzheimer Disease; Aspartic Acid; Brain Chemistry; Choline; Cognitio | 2001 |
Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease.
Topics: Adult; Aged; Brain; Choline; Cognition Disorders; Cohort Studies; Creatine; Female; Hepatitis C; Hum | 2002 |
Nicotine improves cognitive disturbance in rodents fed with a choline-deficient diet.
Topics: Acetylcholine; Animals; Avoidance Learning; Brain; Choline; Choline Deficiency; Cognition Disorders; | 1991 |
(+-)-cis-2-methyl-spiro(1,3-oxathiolane-5,3') quinuclidine (AF102B): a new M1 agonist attenuates cognitive dysfunctions in AF64A-treated rats.
Topics: Alzheimer Disease; Animals; Aziridines; Behavior, Animal; Choline; Cognition Disorders; Disease Mode | 1989 |